HPV legislation in Kentucky

Women in Government Ratings

Women in Government, a non-profit network of state level women legislators, receives significant funding from the pharmaceutical industry, including Merck, GlaxoSmithKline, and Digene Corporation -- all with products related to HPV vaccination and testing. According to their report, "The 'State' of Cervical Cancer Prevention in America - 2008" :

POPULATION: 4,206,074

Incidence & Mortality (2008 Score / 2007 Score)

• Cervical Cancer Incidence Rate: 89.8/100,000 (1 / 1)
• Cervical Cancer Incidence Rate/Race: White: 9.7 , Black: 12.2
• Cervical Cancer Mortality Rate: 2.0/100,000 (2 / 1)
• Cervical Cancer Mortality Rate/Race: White: 1.8, Black: 5.9

Screening (2008 Score / 2007 Score)

• Cervical Cancer Screening Rate: 83.1% (1 / 1)
• Cervical Cancer Screening Rate/Race: White: 83.2%, Black: 86.7%
• % Uninsured/Unscreened: 24.3% (1 / 1)
• Medicaid Coverage HPV Testing: Unrestricted (2 / 2)

Healthcare Access (2008 Score / 2007 Score)

• Rate Uninsured Women: 16% (1 / 1)
• % Low Income/Uninsured Women: 31%

Policy Initiatives and Infrastructure (2008 Score / Cumulative Score (2005–2008)

Screening Requirements (0 / 0)

• There are no new screening requirements.

Task Forces (0 / 1)

• There is no new cervical cancer prevention task force legislation.

Access to HPV Vaccines (1 / 1)

• HB 327 would appropriate $4.1 million to provide the HPV vaccine to uninsured females age 9–26; had 2nd reading , reported favorability.
• HB 143 would require HPV vaccination for all female middle-school students; did not leave committee.
• HB 345 would require exceptions for the HPV vaccination requirement and allow parents to withhold consent for any reason. Amended to delete mandatory vaccination requirement and have Dept. of Health recommend voluntary vaccination; passed House, sent to Senate.

HPV Vaccine Information Programs (0 / 0)

• There is no HPV vaccine information activity.

Miscellaneous (1 / 1)

• SR 21 recognizes January as Cervical Cancer Prevention Month; passed.

Annual Ratings

• 2008: Good (11 out of 22 points)
• 2007: Good (9 out of 18 points)

Articles and resources

SourceWatch Resources

• Gardasil
• GlaxoSmithKline
• Merck
• Women in Government
• Edelman
• The Marketing of Gardasil in Australia
• The Marketing of Gardasil in Canada
• The Marketing of Gardasil in Europe
• The Marketing of Gardasil in New Zealand
• The Marketing of Gardasil in the United States
• Direct-to-consumer advertising
• Disease Mongering
• Drug industry

External links

• Judith Siers-Poisson, The Politics and PR of Cervical Cancer, a four part series, PRWatch.org, July, 2007.